Alzheimer (2)
Clinical trial of a new compound that is being developed for Alzheimer.
- Rauchen
- Rauchen
- Geschlecht
- Mann oder Frau
- Alter
- 45-70 jaar
The tolerability and safety after a single dose of the study compound will be investigated in this trial. From 24 hours prior to administration until 48 hours after administration on day 1 of the clinical trial your heart rhythm will be monitored. This is done by means of stickers (electrodes) on the upper body that are attached to a device (recorder).
Note:
As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:
As a male you can only participate if you have been sterilized for at least 3 months prior to the medical screening.
The trial consists of 1 period during which you will stay in the research facility in Groningen for 9 days (8 nights), followed by 2 short visits. The follow-up visit will take place between 14 and 21 days after your departure from the research facility.
PLEASE NOTE: You must be available for all dates to be able to participate in this trial. The current dates of the trial will be published on our website. These are the currently planned dates; however, these may be subject to change.
Group A4b | |
9 days stay |
|
short visit |
|
follow-up |
|
Group A4c | |
9 days stay |
|
short visit |
|
follow-up |
|
Group A4d | |
9 days stay |
|
short visit |
|
follow-up |
|
Group B1a | |
9 days stay |
|
short visit |
|
follow-up |
|
Group B1b | |
9 days stay |
|
short visit |
|
follow-up |
|
Travel expenses will be reimbursed based on the distance traveled (€ 0.19 net per kilometer) with a minimum of € 12 and a maximum of € 160 (840 kilometers) per round trip, regardless of the mode of transportation.